MedSIR
Business Services · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
45 N Broad St, Ridgewood, New Jersey, 07...Phone Number
+34 932214135Website
www.medsir.orgRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About MedSIR
MEDSIR is a research organization based in Barcelona, specializing in the design and management of strategic clinical trials in oncology. The company aims to foster global collaborations between clinical investigators and pharmaceutical companies to develop innovative cancer treatments. With a focus on improving the lives of cancer patients, MEDSIR also provides resources and support through its online portal for patients and caregivers. Established in 2012, MEDSIR has expanded its reach to over 14 countries, celebrating over a decade of advancing cancer research through collaboration and scientific excellence.Explore more
MedSIR Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MedSIR your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if MedSIR has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when MedSIR launches new products
Click to see if MedSIR had a recent Job posting/layoffs
Check out if MedSIR is spiking on competitors!
MedSIR, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at MedSIR
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on MedSIR recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once MedSIR has new funding data
Recommended Actions
Find VP level buyers at MedSIR
Find 2 more new buyers
Compare Similar Companies to MedSIR
Compare insights from companies similar to MedSIR, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MedSIR is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MedSIR is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MedSIR.
MedSIR Tech Stack
A closer look at the technologies used by MedSIR
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Hiring Plans
MedSIR News & Media
PHERGain and PHERGain-2 advance therapeutic de-escalation in early HER2-positive breast cancer in selected patients
Results from the PHERGain study confirm that the combination of two targeted agents allows one third of patients to be treated without chemotherapy and achieves disease-free survival rates close to 90% five years after surgery. The PHERGain-2 trial, published simultaneously in the...The PHERGuide study demonstrates the utility of circulating tumor DNA for the early detection and real-time monitoring of localized HER2+ breast cancer
The results of the PHERGuide study, presented during the 2025 San Antonio Breast Cancer Symposium (SABCS), demonstrate that the presence of circulating tumor DNA (ctDNA) is associated with disease stage. This research paves the way for the use of blood-based ctDNA as a non-invasive tool...New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options
CHICAGO--(BUSINESS WIRE)--Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious complications associated withMEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead’s Trodelvy® in Advanced Breast Cancer
LAUSANNE, Switzerland & BARCELONA, Spain--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, and MEDSIR (www.medsir.org), a Spanish and US-based, international and innovative research organization in clinical oncology, today announced that the first patient has been dosed in the WIN-B clinical trial evaluating the safety and efficacy of Debio 0123 plus
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MedSIR
Sign Up For FreeTo access detailed company insights
MEDSIR is a research organization based in Barcelona, specializing in the design and management of strategic clinical trials in oncology. The company aims to foster global collaborations between clinical investigators and pharmaceutical companies to develop innovative cancer treatments. With a focus on improving the lives of cancer patients, MEDSIR... Read More
